Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin: 2009-2025

Historic EBT Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 24.96%.

  • Gyre Therapeutics' EBT Margin rose 954.00% to 24.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.24%, marking a year-over-year increase of 8834.00%. This contributed to the annual value of 21.95% for FY2024, which is 8979.00% up from last year.
  • Per Gyre Therapeutics' latest filing, its EBT Margin stood at 24.96% for Q3 2025, which was up 198.58% from 8.36% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year EBT Margin high stood at 45.93% for Q1 2024, and its period low was -1,830.73% during Q1 2022.
  • In the last 3 years, Gyre Therapeutics' EBT Margin had a median value of 21.01% in 2025 and averaged -13.36%.
  • As far as peak fluctuations go, Gyre Therapeutics' EBT Margin plummeted by 150,359bps in 2021, and later soared by 185,588bps in 2023.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' EBT Margin stood at -832.34% in 2021, then skyrocketed by 80,987bps to -22.46% in 2022, then plummeted by 34,691bps to -369.38% in 2023, then skyrocketed by 37,215bps to 2.77% in 2024, then soared by 954bps to 24.96% in 2025.
  • Its last three reported values are 24.96% in Q3 2025, 8.36% for Q2 2025, and 21.01% during Q1 2025.